Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent DevelopmentsBusiness Wire • 05/13/24
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid PriceBusiness Wire • 02/27/24
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.Business Wire • 02/27/24
Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical ResearchBusiness Wire • 02/07/24
Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q FilingBusiness Wire • 11/17/23
Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent DevelopmentsBusiness Wire • 11/15/23
Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA ReviewBusiness Wire • 10/31/23
Virpax Pharmaceuticals Announces Extension of CRADA with the U.S. Army Institute of Surgical ResearchBusiness Wire • 10/12/23
Virpax Pharmaceuticals Announces Results of Probudur™ Dose Escalation StudiesBusiness Wire • 09/27/23
Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like VirusesBusiness Wire • 09/21/23
Virpax® Pharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment ConferenceBusiness Wire • 08/28/23
Virpax Pharmaceuticals Reports 2023 Second Quarter Results and Recent DevelopmentsBusiness Wire • 08/14/23
Virpax Pharmaceuticals Files Provisional Patent Application for NSAID Formulation and MethodBusiness Wire • 08/10/23
Virpax Pharmaceuticals Reports 2023 First Quarter Results and Recent DevelopmentsBusiness Wire • 05/12/23